patent.fyi
Applications  /  US 2026/0355156
United States Patent Application Publication

US 2026/0355156 A1

Published
Nov 12, 2026
Filed
Jun 24, 2026
Earliest date on the face
Jun 24, 2026
Classification
A61K 31/4045
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Glutamate receptor modulation

What ifWhat if the neuroplasticity component used an arylcyclohexylamine that acts at glutamate receptors?
Claim language“a tryptamine-based compound”

An arylcyclohexylamine such as ketamine blocks the open ion channel of an NMDA receptor. A patch-clamp assay measures the reduction in current during repeated receptor activation.

1.2Two pathway targets

What ifWhat if the coordinated modulators targeted exactly two categories, inflammation and mitochondrial function?
Claim language“target at least four aging-pathway categories”

A cytokine-neutralizing antibody binds a selected inflammatory cytokine, and a coenzyme Q10 preparation supplies an electron carrier used by the mitochondrial respiratory chain. A cytokine activity assay and a cellular oxygen-consumption assay provide a separate readout for each target.

1.2Selection by receptor activity

What ifWhat if the tryptamine amount was selected for serotonin receptor activation while sirtuin 1 expression and activity stayed at baseline?
Claim language“upregulates sirtuin 1 (SIRT1)”

A calcium-flux assay measures activation in cells expressing the serotonin 2A receptor. An immunoassay and a deacetylation assay check that sirtuin 1 abundance and activity stay within predefined baseline tolerances at the selected exposure.

1.2Ratios based on drug clearance

What ifWhat if the relative amounts were set from estimated drug clearance and predefined exposure targets?
Claim language“corresponds to a pathway-dominance profile of a subject”

Timed plasma samples and a pharmacokinetic model estimate apparent clearance for each active ingredient. The system calculates each amount from its clearance estimate and target exposure, then calculates the ratios from those amounts.

1.2One multi-target modulator

What ifWhat if the tryptamine was paired with a single modulator that acts on multiple cellular processes?
Claim language“a combination of coordinated aging-pathway modulators”

A single rapamycin active ingredient forms a complex with an intracellular binding protein and inhibits a kinase complex that regulates protein synthesis and autophagy. Phosphorylation of a downstream substrate and autophagic flux provide separate assay readouts for the two processes.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Pathway profiling in neural tissue cultures

A laboratory platform distributes donor-derived neural spheroids across replicate wells and reserves matched wells for vehicle controls. Baseline assays rank cellular senescence, mitochondrial function, oxidative stress, and neuroplasticity against distributions from control cultures of the same age. A liquid handler combines psilocin with pathway modulators at ratios drawn from a predefined table indexed by the four ranks. Follow-up measurements from sister wells guide selection of the next mixture for each donor line.

Component substitution

Mitochondrial support with coenzyme Q10

Coenzyme Q10 replaces the nicotinamide adenine dinucleotide precursor in the mitochondrial component of the mixture and serves as an electron carrier in the mitochondrial respiratory chain. A ratio table maps the mitochondrial function score to a coenzyme Q10 amount relative to the tryptamine component. Separate entries in the same table set the amounts of modulators for cellular senescence, inflammation, and neuroplasticity. Follow-up measurements of mitochondrial respiration update the mitochondrial score used for the next formulation.

Telomere scoring by fluorescence in situ hybridization

Flow cytometric fluorescence in situ hybridization replaces amplification-based telomere measurement in the biomarker panel. A fluorescent peptide nucleic acid probe binds telomeric repeats, and a flow cytometer measures the signal in gated lymphocyte and granulocyte populations alongside an internal reference cell population. The software converts the normalized signals to age-adjusted scores and uses their mean as the telomere maintenance score. This score joins the other pathway scores in the table that sets the modulator ratios relative to the tryptamine component.

Parameter or scale variation

Six pathway scores with replicate measurements

The biomarker panel covers cellular senescence, mitochondrial function, inflammation, oxidative stress, epigenetic aging, and neuroplasticity. Two baseline collections occur seven days apart, and each marker score uses the mean of the two standardized measurements. The six pathway scores map to four preset ratio bands for the corresponding modulators relative to the tryptamine component. Follow-up collections every 28 days trigger a review when a pathway score differs from its predicted value by at least one reference standard deviation at two consecutive visits.

Combination with existing systems

Integration with pharmacy gravimetric verification

A pharmacy compounding system receives a reviewed formulation record with a target mass and tolerance for the tryptamine component and each of at least four pathway modulators. Barcode scans match each source container to its ingredient record, and a connected balance records the incremental mass during dispensing. The system holds the formulation for review when a measured mass falls outside its tolerance and records the actual ingredient ratios with the batch identifier. Follow-up biomarker records use that identifier to associate each observation with the measured composition.

Automated or data-driven variant

Bayesian updating of predicted biomarker trajectories

A Bayesian state-space model estimates a latent severity score for each pathway from serial biomarkers, assay variability, and collection times. At each visit, the software compares the new measurements with the predictive intervals generated before those measurements entered the model. When a pathway falls outside its interval at two consecutive visits, the software updates the trajectory and ranks predefined modulator ratios by predicted deviation from target scores. The review screen displays the current and proposed ratios relative to the tryptamine component alongside the measurements that triggered the update.

Specific version of a part

Crystalline psilocybin active ingredient

Crystalline psilocybin serves as the tryptamine active ingredient in a dry granulate with a cellulose filler. A chromatographic assay measures psilocybin content and separately quantifies psilocin formed during storage.

Four category modulator panel

A senolytic compound targets senescent-cell survival, coenzyme Q10 participates in mitochondrial electron transport, and a cyclooxygenase inhibitor reduces inflammatory prostaglandin synthesis. N-acetylcysteine supplies cysteine for glutathione synthesis to address oxidative stress.

Biomarker weighted ingredient ratios

Software converts each biomarker to a standardized deviation from a reference distribution and orients the score so that larger values indicate greater impairment. The system averages scores within each pathway and uses a bounded lookup table to assign each modulator an amount relative to a fixed tryptamine amount.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2025/0177422 A1
Published
Jun 5, 2025
Filed
Nov 8, 2024
Class
A61K 31/675
Document BUS 2025/0375420 A1
Published
Dec 11, 2025
Filed
Jun 5, 2023
Class
A61K 31/4045
Claim 1
Document A
Document B
1.1a tryptamine-based compound selected from the group consisting of psilocin, psilocybin, and a non-hallucinogenic structural analog of psilocin
In one embodiment, the active ingredient is a crystalline form of psilocybin and psilocin, such as co-crystal Form A, co-crystal Form B or co-crystal Form C described herein.
A · US 2025/0177422 A1 · ¶ 254
In one embodiment, the active ingredient is a crystalline form of psilocybin and psilocin, such as crystalline Form A, crystalline Form B or From C described herein.
B · US 2025/0375420 A1 · ¶ 114
1.2a combination of coordinated aging-pathway modulators that together target at least four aging-pathway categories selected from the group consisting of cellular senescence, mitochondrial function, inflammation, oxidative stress, genomic stability, telomere maintenance, epigenetic aging, and neuroplasticity, wherein the tryptamine-based compound is present in an amount that upregulates sirtuin 1 (SIRT1), and wherein a relative ratio of the tryptamine-based compound to each of the coordinated aging-pathway modulators corresponds to a pathway-dominance profile of a subject.
It was found that treatment with the psilocybin+psilocin in a 1:1 molar ratio combination resulted in an approximate 20% increase in neurogenesis from single dosing over six hours with a matching decrease in proliferation. Neuronal length two days after administration was observed to be greatest with the psilocybin+psilocin in a 1:1 molar ratio combination, approximately doubling at the highest dose and greater than psilocybin alone.
B · US 2025/0375420 A1 · ¶ 237

An empty cell means only that no passage was reproduced there.

Statements in these documents
The psilocybin and psilocin co-crystal may further be used to induce neuroplasticity and increase brain-derived neurotrophic factor (BDNF) levels, all with a lowered risk of cardiac adverse events.
A · US 2025/0177422 A1 · ¶ 2
However, there has been far less research on the potential clinical benefits of longer-term microdosing, although there are a large number of anecdotal reports and poorly controlled studies purporting to demonstrate a wide range of benefits.
A · US 2025/0177422 A1 · ¶ 5
In contrast to psilocybin, psilocin is chemically unstable and rapidly oxidizes when exposed to air.
B · US 2025/0375420 A1 · ¶ 4
One such treatment may be a crystalline form of psilocybin and psilocin, especially for use in disorders resistant to current treatments.
B · US 2025/0375420 A1 · ¶ 7
Cite aspatent.fyi, US 2026/0355156 A1, claim 1, first published 2026-11-19T08:28:42-05:00, https://patent.fyi/US20260355156/, SHA-256 7848083a779c34eae0df1ce626a5c3da4281fc24763287eddd76e736185d928c
First published
Permanent addresshttps://patent.fyi/US20260355156/
Content fingerprint (SHA-256)7848083a779c34eae0df1ce626a5c3da4281fc24763287eddd76e736185d928c
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi